Audentes Therapeutics

OverviewSuggest Edit

Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for patients with serious, rare diseases through the application of gene therapy technology. The Company currently has four programs in development: AT132 for the treatment of X-Linked Myotubular Myopathy, an ultra-rare, severe, debilitating disease that affects skeletal muscles. AT342 for the treatment of Crigler-Najjar Syndrome, a rare, congenital autosomal recessive monogenic disease characterized by severely high levels of bilirubin in the blood and risk of irreversible neurological damage and death. AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia, an inherited disease characterized by abnormal ventricular heartbeats. AT982 for the treatment of Pompe disease, a rare, inherited disorder characterized by progressive muscle weakness and respiratory impairment.
TypePublic
Founded2013
HQSan Francisco, US
Websiteaudentestx.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Dec 2018)207(+37%)
Job Openings10
Share Price (Jun 2019)$37.2 (-6%)

Key People/Management at Audentes Therapeutics

Matthew Patterson

Matthew Patterson

President & CEO

Audentes Therapeutics Office Locations

Audentes Therapeutics has an office in San Francisco
San Francisco, US (HQ)
600 California St, San Francisco
Show all (1)

Audentes Therapeutics Financials and Metrics

Audentes Therapeutics Revenue

USD

Net income (Q1, 2019)

(49.4m)

EBIT (Q1, 2019)

(51.8m)

Market capitalization (10-Jun-2019)

1.6b

Closing stock price (10-Jun-2019)

37.2

Cash (31-Mar-2019)

133.2m
Audentes Therapeutics's current market capitalization is $1.6 b.
Annual
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

11.3m17.3m30.0m

R&D expense

48.8m75.9m104.4m

Operating expense total

60.0m93.2m134.4m

EBIT

(60.0m)(93.2m)(134.4m)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

General and administrative expense

2.5m2.9m3.7m4.1m4.3m6.5m6.3m7.8m12.0m

R&D expense

11.7m12.5m14.6m18.8m20.9m19.9m26.3m29.9m39.8m

Operating expense total

14.2m15.5m18.2m22.8m25.2m26.4m32.6m37.7m51.8m

EBIT

(14.2m)(15.5m)(18.2m)(22.8m)(25.2m)(26.4m)(32.6m)(37.7m)(51.8m)
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

36.4m39.0m144.3m

Current Assets

108.4m137.0m419.8m

PP&E

18.9m24.4m32.1m

Goodwill

3.6m3.6m3.6m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(59.7m)(90.2m)(128.8m)

Depreciation and Amortization

1.6m3.4m5.6m

Accounts Payable

(671.0k)686.0k4.1m

Cash From Operating Activities

(49.0m)(84.5m)(108.0m)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(24.6m)(40.0m)(18.1m)(40.9m)(65.9m)(25.6m)(56.9m)(93.2m)(49.4m)

Depreciation and Amortization

289.0k932.0k732.0k1.5m2.4m1.1m2.4m3.9m1.7m

Accounts Payable

(1.2m)(1.1m)(1.2m)640.0k1.2m596.0k(209.0k)(724.0k)1.9m

Cash From Operating Activities

(26.5m)(36.5m)(22.6m)(38.6m)(61.6m)(24.6m)(47.9m)(79.5m)(42.2m)
USDY, 2019

Financial Leverage

1.1 x
Show all financial metrics

Audentes Therapeutics Online and Social Media Presence

Embed Graph

Audentes Therapeutics Blogs

Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update Content Import Tue, 08/06/2019 - 16:02 Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update 08/06/19 This release is …

Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019

Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019 Content Import Tue, 07/30/2019 - 08:01 Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 20…

Audentes Therapeutics Announces Changes to Senior Management Team

Audentes Therapeutics Announces Changes to Senior Management Team Content Import Wed, 05/29/2019 - 16:01 Audentes Therapeutics Announces Changes to Senior Management Team 05/29/19 This release is a backfill from a News Wire General -…

Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy

- Platform expansion combines the delivery power of AAV with the precision tools of antisense oligonucleotides to develop best-in-class treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) - Exclusive license agreement with the Research Institute at Nationwide

Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer

Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer Content Import Mon, 04/01/2019 - 08:09 Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Tho…

Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases

Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases Content Import Thu, 02/28/2019 - 08:10 Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Pro…
Show more

Audentes Therapeutics Frequently Asked Questions

  • When was Audentes Therapeutics founded?

    Audentes Therapeutics was founded in 2013.

  • Who are Audentes Therapeutics key executives?

    Audentes Therapeutics's key executives are Matthew Patterson.

  • How many employees does Audentes Therapeutics have?

    Audentes Therapeutics has 207 employees.

  • Who are Audentes Therapeutics competitors?

    Competitors of Audentes Therapeutics include Sema4, Futura Genetics and Human Longevity.

  • Where is Audentes Therapeutics headquarters?

    Audentes Therapeutics headquarters is located at 600 California St, San Francisco, San Francisco.

  • Where are Audentes Therapeutics offices?

    Audentes Therapeutics has an office in San Francisco.

  • How many offices does Audentes Therapeutics have?

    Audentes Therapeutics has 1 office.